Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 27Lung Neoplasms 12Neoplasms 5Colorectal Neoplasms 5Neoplasm Metastasis 4Advanced Solid Tumors 3Pancreatic Neoplasms 2Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation 2Venous Thromboembolism 1Thoracic Neoplasms 1Solid Tumor, Adult 1Solid Tumor 1Sexual Dysfunction, Physiological 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Ovarian Neoplasms 1Noonan Syndrome 1Non-small Cell Lung Cancer Metastatic 1Non Small Lung Cancer 1Neoplasms by Site 1Mesothelioma 1Lung Diseases 1KRAS p.G12C Mutant Advanced Solid Tumors 1KRAS p, G12c Mutated /Advanced Metastatic NSCLC 1Hereditary Sensory and Autonomic Neuropathies 1Healthy Participants 1Fallopian Tube Neoplasms 1Eunuchism 1Erectile Dysfunction 1Endometrial Neoplasms 1

Interventions

sotorasib 22'-((4'-trifluoromethanesulfonyloxy)phenyl)-N-methanesulfonylpropionamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation × sotorasib × Clear all
NCT05815173 2025-12-30

Ladarixin With Sotorasib in Advanced NSCLC

NYU Langone Health

Phase 1 Recruiting
40 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation

NCT05815186 2024-03-29

Ladarixin With Sotorasib in Advanced NSCLC - Phase II

NYU Langone Health

Phase 2 Withdrawn
Thoracic

Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡